1-(Hexyloxy)propan-2-one | 40657-09-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(Hexyloxy)propan-2-one
• 英文别名: 1-Hexoxypropan-2-one
• CAS: 40657-09-8
• 化学式: C₉H₁₈O₂
• 分子量: 158.241
• InChiKey: APOKGGYUGXMFNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  乙二醇己醚 在 草酰氯 、 戴斯-马丁氧化剂 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 1-(Hexyloxy)propan-2-one
  参考文献：
  名称：

  从头算的使用来预测羧酸酯酶抑制剂的生物学效能。

  摘要：

  羧酸酯酶是重要的酶，负责许多药物和异生物素的水解和代谢。这些酶被含有三氟甲基酮（TFK）的抑制剂有效抑制。我们证明了酮的水合状态受周围化学部分的影响，并且与抑制剂的效力有关，而有利于宝石二醇构象的抑制剂表现出更大的效力。进行了从头算来确定酮的水合能量，并且该值与一系列羧酸酯酶抑制剂的酯酶抑制数据相关。在三种不同的哺乳动物模型（人肝微粒体，鼠肝微粒体和商品猪肝酯酶）和昆虫酶制剂（少年激素酯酶）中检查了该系统。在所有情况下，酮的水合程度都与生物学效能密切相关。我们的结果显示与水合程度非常相关，占人类肝微粒体酯酶抑制活性的94％（p <0.01）。TFK中羰基碳原子上的原子电荷也与抑制剂效能密切相关，占人类肝微粒体抑制活性的94％（p <0.01）。此外，我们提供了含硫抑制剂分子内氢键的结晶学证据，并将这些数据与宝石二醇的形成相关。这项研究提供了对羧酸酯酶抑制机制的见解，并提出了过于强烈地支持宝

  DOI：

  10.1021/jm020072w

文献信息

• ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Yale University

  公开号：US20160045607A1

  公开（公告）日：2016-02-18

  The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

  本发明涉及双功能化合物，其作为靶向泛素化的调节剂具有实用性，特别是根据本发明抑制各种多肽和其他蛋白质的抑制剂。具体而言，本发明涉及一种在一端含有结合泛素连接酶的VHL配体，另一端含有结合靶蛋白的基团的化合物，使得靶蛋白位于靠近泛素连接酶以实现对该蛋白的降解（和抑制）。本发明展示了与根据本发明的化合物相关的广泛的药理活性范围，与靶向多肽的降解/抑制一致。
• [EN] PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE<br/>[FR] PIPERIDINES, PYRROLIDINES ET HEXAHYDRO-1H-AZEPINES FAVORISANT LA LIBERATION DE L'HORMONE DE CROISSANCE
  申请人：MERCK & CO., INC.

  公开号：WO1995013069A1

  公开（公告）日：1995-05-18

  (EN) The present invention is directed to certain piperidine, pyrrolidine, and hexahydro-1H-azepine compounds of general structural formula (I) wherein R1, R3, R4, R5, A, W, X, Y, and n are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such compounds as the active ingredient thereof are also disclosed.(FR) L'invention concerne certains composés de pipéridine, de pyrrolidine, et d'hexahydro-1H-azépine de formule structurale (I) dans laquelle R1, R3, R4, R5, A, W, X, Y et n sont définis dans la description. Ces composés favorisent la libération de l'hormone de croissance chez les humains et les animaux. Cette propriété peut être utilisée pour favoriser la croissance d'animaux destinés à l'alimentation et augmenter la production de produits de viande comestibles, et, chez les humains, pour traiter des états physiologiques ou médicaux caractérisés par une insuffisance de sécrétion de l'hormone de croissance telle que l'insuffisance staturale chez l'enfant, et traiter des états médicaux pouvant être améliorés par les effets anabolisants de l'hormone de croissance. L'invention porte également sur des compositions libérant l'hormone de croissance dans lesquelles lesdits composés sont utilisés comme principes actifs.

  本发明涉及通式（I）中R1、R3、R4、R5、A、W、X、Y和n所定义的某些哌啶、吡咯烷和六氢-1H-氮杂环化合物。这些化合物促进人类和动物的生长激素释放。这种特性可用于促进食用动物的生长，使可食肉类产品的生产更加高效，以及在人类中，用于治疗生长激素分泌不足所表现出的生理或医学状况，例如生长激素缺乏症儿童的矮小症，以及治疗通过生长激素的合成代谢作用得到改善的医学状况。还公开了含有该化合物作为活性成分的生长激素释放组合物。
• Novel anilide compounds and pharmaceutical compositions comprising them
  申请人：——

  公开号：US20020037910A1

  公开（公告）日：2002-03-28

  The invention provides novel anilide compounds and pharmaceutical compositions comprising them. The invention relates to compounds of a formula: 1 wherein Ar is an optionally-substituted aryl group; R 4 and R 5 are the same or different, and each is a hydrogen atom, a lower alkyl group, or a lower alkoxy group; and R 4 and R 5 may together form a lower alkylene group of which one or more methylene moieties may optionally be substituted by oxygen and/or sulfur atoms; X is —NH—, or an oxygen or sulfur atom; Y is —NH—, an oxygen or sulfur atom, or a sulfoxide or sulfone group; Z is a single bond, or —NR 6 —; R 6 represents a hydrogen atom or a lower alkylene group; and n is an integer of from 0 to 15; and their salts and solvates. The compounds of the invention are useful as pharmaceutical compositions, especially as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitors.

  本发明提供了新型苯甲酰胺类化合物及其制备的药物组合物。本发明涉及一种公式1的化合物：其中Ar是可选取的取代芳基基团；R4和R5相同或不同，每个为氢原子、低碳基基团或低氧基基团；R4和R5可以共同形成一个低碳基烷基，其中一个或多个亚甲基团可以选择性地被氧和/或硫原子取代；X为—NH—或氧或硫原子；Y为—NH—、氧或硫原子或亚砜基或砜基团；Z为单键或—NR6—；R6表示氢原子或低碳基烷基；n为0至15的整数；以及它们的盐和溶剂化物。本发明的化合物可用作药物组合物，特别是作为酰基辅酶A胆固醇酰基转移酶（ACAT）抑制剂。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas, Inc.

  公开号：US20160214972A1

  公开（公告）日：2016-07-28

  The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.

  本发明涉及双功能化合物，其可用于降解和（抑制）雄激素受体。具体而言，本发明涉及含有一端结合到泛素连接酶的VHL配体和另一端结合雄激素受体的基团的化合物，使得雄激素受体靠近泛素连接酶，从而使雄激素受体发生降解（和抑制）。本发明展现了广泛的药理活性，与本发明的化合物的降解/抑制雄激素受体的作用一致。
• COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS
  申请人：Arvinas, Inc.

  公开号：US20160272639A1

  公开（公告）日：2016-09-22

  The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

  本发明涉及双功能化合物，其作为靶向泛素化的调节剂具有实用性，特别是本发明的双功能化合物可以抑制多种蛋白质和其他蛋白质，这些蛋白质通过本发明的双功能化合物被降解和/或被抑制。具体而言，本发明涉及一端含有结合泛素连接酶的VHL配体，另一端含有结合靶蛋白的基团，使得靶蛋白靠近泛素连接酶，从而降解（和抑制）该蛋白质。本发明展示了与本发明化合物相关的广泛的药理活性，与靶向多肽的降解/抑制一致。